1. Home
  2. PRME vs CXII Comparison

PRME vs CXII Comparison

Compare PRME & CXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

SELL

Current Price

$4.23

Market Cap

526.0M

Sector

Health Care

ML Signal

SELL

CXII

Churchill Capital Corp XII Class A Ordinary Shares

N/A

Current Price

$10.49

Market Cap

597.4M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
PRME
CXII
Founded
2019
2026
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
526.0M
597.4M
IPO Year
2022
2026

Fundamental Metrics

Financial Performance
Metric
PRME
CXII
Price
$4.23
$10.49
Analyst Decision
Buy
Analyst Count
13
0
Target Price
★ $7.03
N/A
AVG Volume (30 Days)
★ 5.5M
27.3K
Earning Date
11-12-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
★ 18.18
N/A
EPS
N/A
★ N/A
Revenue
★ $4,632,000.00
N/A
Revenue This Year
$18.58
N/A
Revenue Next Year
$23.34
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 55.28
N/A
52 Week Low
$2.67
$10.05
52 Week High
$5.91
$10.99

Technical Indicators

Market Signals
Indicator
PRME
CXII
Relative Strength Index (RSI) 51.32 44.45
Support Level $2.94 $10.34
Resistance Level $4.80 $10.45
Average True Range (ATR) 0.53 0.03
MACD -0.08 0.02
Stochastic Oscillator 22.25 41.18

Price Performance

Historical Comparison
PRME
CXII

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

About CXII Churchill Capital Corp XII Class A Ordinary Shares

Churchill Capital Corp XII is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Share on Social Networks: